Transfection with anti-p65 intrabody suppresses invasion and angiogenesis in glioma cells by blocking nuclear factor-κB transcriptional activity

Clinical Cancer Research

Volumn 13, Issue 7, 2007, Pages 2178-2190

  Li, Liang ^a   Gondi, Christopher S ^a   Dinh, Dzung H ^b   Olivero, William C ^b   Gujrati, Meena ^b   Rao, Jasti S ^a,b  

^a Department of Cancer Biology and Pharmacology   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; P65 ANTIBODY; PROTEIN ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DNA BINDING; DRUG INHIBITION; ENDOTHELIUM CELL; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; TUMOR GROWTH;

AMINO ACID SEQUENCE; ANTIBODIES; ANTIBODY SPECIFICITY; BASE SEQUENCE; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CLONING, MOLECULAR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GLIOMA; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 34247528447     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1711     Document Type: Article

References (43)

1. Cavenee WK, Furnari FB, Nagane M. Diffusely infiltrating astrocytomas. In: Kleihues P, Cavenee WK, editors. Tumors of the nervous system. Lyon: IARC Press; 2000. p. 9-51.
2. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985;56:1106-11.
3. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
4. Ravi R, Bedi A. NF-κB in cancer - a friend turned foe. Drug Resist Updat 2004;7:53-67.
5. Kanzawa T, Ito H, Kondo Y, Kondo S. Current and future gene therapy for malignant gliomas. J Biomed Biotechnol 2003;2003:25-34.
6. Wang H, Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN. Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas. Lab Invest 2004;84:941-51.
7. Buss H, Dorrie A, Schmitz ML, et al. Phosphorylation of serine 468 by GSK-3β negatively regulates basal p65 NF-κB activity. J Biol Chem 2004;279:49571-4.
8. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1- stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999;274:26448-53.
9. Wang D, Westerheide SD, Hanson JL, Baldwin AS, Jr. Tumor necrosis factor α-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000;275:32592-7.
10. Schmitz ML, dos Santos Silva MA, Baeuerle PA. Transactivation domain 2 (TA2) of p65 NF-κB. Similarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. J Biol Chem 1995;270:15576-84.
11. Gondi CS, Lakka SS, Dinh D, Olivero W, Gujrati M, Rao JS. Down-regulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biology 2004;1:165-76.
12. Lakka SS, Gondi CS, Yanamandra N, et al. Synergistic down-regulation of urokinase plasminogen activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res 2003;63:2454-61.
13. Heng BC, Cao T. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody). Med Hypotheses 2005;64:1105-8.
14. Popkov M, Jendreyko N, Gonzalez-Sapienza G, Mage RG, Rader C, Barbas CF III. Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. J Immunol Methods 2004;288:149-64.
15. Wheeler YY, Chen SY, Sane DC. Intrabody and intrakine strategies for molecular therapy. Mol Ther 2003;8:355-66.
16. Wagner RW, Flanagan WM. Antisense technology and prospects for therapy of viral infections and cancer. Mol Med Today 1997;3:31-8.
17. Beerli RR, Barbas CF III. Engineering polydactyl zinc-finger transcription factors. Nat Biotechnol 2002;20:135-41.
18. Hannon GJ. RNA interference. Nature 2002;418:244-51.
19. Caron dF, Gruel N, Venot C, et al. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene 1999;18:551-7.
20. Mary MN, Venot C, Caron de Fromentel C, et al. A tumor specific single chain antibody dependent gene expression system. Oncogene 1999;18:559-64.
21. Rajpal A, Turi TG. Intracellular stability of anti-caspase-3 intrabodies determines efficacy in retargeting the antigen. J Biol Chem 2001;276:33139-46.
22. Ramm K, Gehrig P, Pluckthun A. Removal of the conserved disulfide bridges from the scFv fragment of an antibody: effects on folding kinetics and aggregation. J Mol Biol 1999;290:535-46.
23. Wu Y, Duan L, Zhu M, et al. Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 rev: variations in viral inhibition. J Virol 1996;70:3290-7.
24. Zhu Q, Zeng C, Huhalov A, et al. Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7. J Immunol Methods 1999;231:207-22.
25. Amstutz P, Forrer P, Zahnd C, Pluckthun A. In vitro display technologies: novel developments and applications. Curr Opin Biotechnol 2001;12:400-5.
26. der Maur AA, Zahnd C, Fischer F, et al. Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework. J Biol Chem 2002;277:45075-85.
27. Strube RW, Chen SY. Enhanced intracellular stability of sFv-Fc fusion intrabodies. Methods 2004;34:179-83.
28. Worn A, Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001;305:989-1010.
29. Chintala SK, Tonn JC, Rao JS. Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci 1999;17:495-502.
30. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003;(415 Suppl):S46-58.
31. Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol 2000;50:109-20.
32. Hasan J, Jayson GC. VEGF antagonists. Expert Opin Biol Ther 2001;1:703-18.
33. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995;270:19761-6.
34. Kerr DJ. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 2004;1:39-43.
35. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
36. Lin P, Sankar S, Shan S, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998;9:49-58.
37. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
38. Pulukuri SM, Gondi CS, Lakka SS, et al. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J Biol Chem 2005;280: 36529-40.
39. Lakka SS, Gondi CS, Yanamandra N, et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004;23:4681-9.
40. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188-97.
41. Sliva D, Rizzo MT, English D. Phosphatidylinositol 3-kinase and NF-κB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 2002;277:3150-7.
42. Sliva D, English D, Lyons D, Lloyd FP, Jr. Protein kinase C induces motility of breast cancers by up-regulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-κB. Biochem Biophys Res Commun 2002;290:552-7.
43. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9-16.